Diuretics are among the most commonly prescribed medications, and the NP must understand the site of action, potency, clinical indications, and monitoring requirements for each class. Loop diuretics (furosemide, bumetanide, torsemide) block the Na-K-2Cl cotransporter in the thick ascending limb of Henle's loop — the most powerful diuretic site, capable of excreting 15-25% of filtered sodium. They are the cornerstone of heart failure decongestive therapy and the preferred diuretic when eGFR <30 mL/min (thiazides lose efficacy below this threshold). Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) block the Na-Cl cotransporter in the distal convoluted tubule, excreting 5-8% of filtered sodium. They are first-line antihypertensives but are ineffective in advanced CKD. Potassium-sparing diuretics include aldosterone antagonists (spironolactone, eplerenone) acting on the collecting duct and epithelial sodium channel blockers (amiloride, triamterene). Key prescribing differences: chlorthalidone is preferred over HCTZ for hypertension (longer half-life, stronger 24-hour BP reduction, better outcomes data); bumetanide and torsemide have more reliable oral bioavailability than furosemide (which varies 10-100%); IV-to-PO furosemide conversion ratio is 1:2 (IV is twice as potent). Diuretic resistance in heart failure requires dose escalation, IV administration,...